New weight Drug's heart effects under microscope in early trial
NCT ID NCT07229157
First seen Nov 16, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-stage study tests whether maridebart cafraglutide, a potential weight-loss drug, affects the heart's electrical activity. About 81 adults with overweight or obesity will receive the drug, a placebo, or a positive control to measure changes in heart rhythm. The goal is to ensure the drug is safe for the heart before moving to larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
Conditions
Explore the condition pages connected to this study.